StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
16
This year
2
Publishing Date
2024 - 03 - 19
1
2024 - 02 - 12
1
2023 - 09 - 20
1
2023 - 09 - 13
1
2023 - 04 - 27
1
2023 - 04 - 11
1
2023 - 03 - 31
1
2022 - 09 - 01
1
2022 - 01 - 31
1
2021 - 10 - 27
1
2021 - 09 - 17
1
2021 - 09 - 15
2
2021 - 08 - 05
1
2021 - 07 - 29
1
2021 - 05 - 20
1
Sector
Health technology
16
Tags
Alliances
16
Antibody
7
Application
11
Approval
20
Asia
14
Biotech
6
Biotech-bay
10
Biotech-beach
17
Cabometyx
7
Cancer
34
Cell carcinoma
7
Children
7
Clinical-trials-phase-ii
10
Clinical-trials-phase-iii
23
Collaboration
15
Covid
11
Covid-19
10
Disease
32
Drug
29
Earnings
23
Events
8
Expected
7
Fda
16
Financial
17
Financial results
13
Gene therapies
6
Gene therapy
6
Genetown
22
Global
51
Growth
29
Hereditary angioedema
8
Injection
6
Japan
7
License
13
Liver
16
Market
84
Money
11
N/a
184
Nivolumab
6
Partnership
6
People
7
Pharmaceutical
17
Phase 2
6
Phase 3
19
Positive
14
Product-news
10
Rare
11
Reach
11
Renal
7
Report
45
Research
41
Results
58
Sars-cov-2
6
Study
8
Takhzyro
7
Therapeutics
37
Therapy
42
Treatment
49
Trial
36
Vaccine
27
Entities
Arrowhead pharmaceuticals, inc.
1
Biogen inc.
1
Exelixis, inc.
2
Hutchison china meditech limited
1
Regenxbio inc.
1
Takeda pharmaceutical company limited
16
Thermo fisher scientific inc
2
Symbols
ABBV
42
ABT
79
ACER
12
ADMA
18
ALPMF
17
ALPMY
17
AMGN
23
AMRX
15
ANIP
17
APYX
12
AQST
15
ARDX
11
ARVL
10
ATXI
10
BCLI
14
BDX
13
BGNE
16
BIIB
32
BLUE
13
BMRN
10
BMY
20
BNTX
24
BSX
11
CHRS
23
EGRX
11
EYEN
13
FBIO
14
FNCTF
63
GILD
21
GSK
14
INCY
23
IONS
13
JAGX
16
JNJ
225
LLY
71
MDT
28
MESO
15
MRK
36
MRNA
13
NVAX
11
NVO
11
NVS
28
NVSEF
22
OCGN
15
PFE
74
PRGO
90
REGN
50
RETA
12
SNGX
14
SNY
236
SNYNF
204
SRNE
21
TAK
16
TEVJF
22
TMO
16
TNXP
12
TTOO
14
VERU
14
VRCA
13
VRTX
14
Exchanges
Nasdaq
5
Nyse
16
Crawled Date
2024 - 03 - 19
1
2024 - 02 - 12
1
2023 - 09 - 20
1
2023 - 09 - 13
1
2023 - 04 - 27
1
2023 - 04 - 11
1
2023 - 03 - 31
1
2022 - 09 - 01
1
2022 - 01 - 31
1
2021 - 10 - 27
1
2021 - 09 - 17
1
2021 - 09 - 15
2
2021 - 08 - 05
1
2021 - 07 - 29
1
2021 - 05 - 20
1
Crawled Time
01:00
1
11:00
1
13:00
2
13:20
2
13:30
1
14:00
2
15:00
1
17:00
1
20:00
2
22:00
2
23:00
1
Source
www.biospace.com
13
www.fda.gov
1
www.globenewswire.com
1
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Fda
symbols :
Tak
save search
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published:
2024-03-19
(Crawled : 17:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-9.13%
|
O:
-0.07%
H:
0.0%
C:
-0.96%
iclusig
fda
drug
takeda
approval
application
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published:
2024-02-12
(Crawled : 14:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-7.09%
|
O:
0.07%
H:
0.46%
C:
0.42%
fda
first
treatment
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
Published:
2023-09-20
(Crawled : 14:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-18.83%
|
O:
0.12%
H:
0.43%
C:
-0.18%
tak-721
fda
resubmission
treatment
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published:
2023-09-13
(Crawled : 13:30)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-16.32%
|
O:
0.63%
H:
0.5%
C:
0.31%
entyvio
fda
disease
active
therapy
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Published:
2023-04-27
(Crawled : 13:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-21.3%
|
O:
0.0%
H:
0.36%
C:
0.3%
entyvio
fda
active
resubmission
therapy
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Published:
2023-04-11
(Crawled : 13:20)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-20.4%
|
O:
-0.36%
H:
0.35%
C:
-0.12%
hyqvia
fda
children
approval
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Published:
2023-03-31
(Crawled : 01:00)
- globenewswire.com
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-19.08%
|
O:
0.0%
H:
0.92%
C:
0.8%
HCM
|
$16.45
-1.38%
-1.4%
290K
|
Health Technology
|
24.48%
|
O:
-1.19%
H:
2.04%
C:
-1.66%
fda
cancer
treatment
submission
Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials
Published:
2022-09-01
(Crawled : 13:20)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-3.78%
|
O:
-0.36%
H:
0.58%
C:
0.29%
isp-001
fda
clearance
trials
application
therapy
mps-ih
mps-i
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
Published:
2022-01-31
(Crawled : 15:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-8.13%
|
O:
-0.14%
H:
0.0%
C:
0.0%
vonvendi
treatment
fda
disease
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
Published:
2021-10-27
(Crawled : 20:00)
- fda.gov
TMO
|
$547.25
-1.32%
-0.02%
1.6M
|
Health Technology
|
-9.43%
|
O:
0.44%
H:
2.01%
C:
0.82%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-4.27%
|
O:
2.03%
H:
3.33%
C:
0.07%
RGNX
|
$17.01
-2.8%
-2.88%
410K
|
Health Technology
|
-50.31%
|
O:
0.91%
H:
2.93%
C:
2.79%
BIIB
|
$192.13
-1.55%
-1.57%
1.3M
|
Health Technology
|
-24.93%
|
O:
0.19%
H:
2.32%
C:
1.7%
disease
fda
gene therapies
therapy
gene therapy
rare
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published:
2021-09-17
(Crawled : 22:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-23.08%
|
O:
-0.06%
H:
0.0%
C:
0.0%
EXEL
4
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
9.83%
|
O:
-0.61%
H:
0.0%
C:
0.0%
fda
fda approval
cancer
approval
FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations
Published:
2021-09-15
(Crawled : 23:00)
- prnewswire.com
TMO
|
$547.25
-1.32%
-0.02%
1.6M
|
Health Technology
|
-1.49%
|
O:
-0.15%
H:
0.12%
C:
-0.3%
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-22.18%
|
O:
0.41%
H:
1.11%
C:
0.76%
fda
therapy
fda approval
diagnostic
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
Published:
2021-09-15
(Crawled : 22:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-21.01%
|
O:
0.6%
H:
1.01%
C:
0.89%
fda
therapy
designation
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published:
2021-08-05
(Crawled : 13:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-19.82%
|
O:
0.0%
H:
0.61%
C:
0.55%
EXEL
4
|
$22.875
0.24%
0.24%
2.8M
|
Health Technology
|
34.37%
|
O:
0.0%
H:
2.03%
C:
1.25%
new drug
fda
cancer
drug
fda acceptance
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Published:
2021-07-29
(Crawled : 20:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-22.77%
|
O:
0.0%
H:
0.06%
C:
-1.17%
ARWR
|
$22.52
-4.86%
-5.11%
1.1M
|
Health Technology
|
-65.38%
|
O:
1.95%
H:
1.82%
C:
-1.98%
disease
liver disease
treatment
fda
therapy
breakthrough therapy
liver
designation
GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012, a Novel Allogeneic Variable Delta 1 Gamma-delta T Cell Cancer Therapy
Published:
2021-05-20
(Crawled : 11:00)
- biospace.com/
TAK
|
$13.15
-0.61%
0.0%
1.6M
|
Health Technology
|
-22.81%
|
O:
0.82%
H:
0.81%
C:
0.23%
fda clearance
fda
therapy
cancer
application
clearance
t-cell
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.